Thieler Law Corp, member of the Investor Attorney Network, is investigating whether members of the board of directors of Sagent Pharmaceuticals Inc (NASDAQ: SGNT) acted responsibly on behalf of investors’ profitability in the planned $736 million sale to Nichi-Iko Pharmaceutical Co Ltd.

On July 11, 2016, Sagent Pharmaceuticals Inc (NASDAQ: SGNT) and Nichi-Iko Pharmaceutical Co Ltd announced that they had entered into a merger agreement. Under the terms of the merger agreement, Nichi-Iko will offer Sagent shareholders $21.75 per share in cash for all outstanding shares.    

Based in Schaumburg, Illinois, and founded in 2006 Sagent Pharmaceuticals Inc develops, sources, manufactures, and markets injectable pharmaceuticals in North America.

The investigation is looking to uncover whether Sagent Pharmaceuticals Inc was undervalued at the cost of the shareholders considering one analyst’s opinion of their stock is valued at $25.00 per share.

If you purchased Sagent Pharmaceuticals Inc (NASDAQ: SGNT) prior to July 11, 2016, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185